Spectrum Pharmaceuticals - Chancen und Risiken? (Seite 288)
eröffnet am 31.08.08 11:55:05 von
neuester Beitrag 10.08.23 11:06:43 von
neuester Beitrag 10.08.23 11:06:43 von
Beiträge: 4.229
ID: 1.143.896
ID: 1.143.896
Aufrufe heute: 2
Gesamt: 285.553
Gesamt: 285.553
Aktive User: 0
ISIN: US84763A1088 · WKN: 164623 · Symbol: NTR
0,8910
EUR
+4,97 %
+0,0450 EUR
Letzter Kurs 31.07.23 Tradegate
Neuigkeiten
| TitelBeiträge |
|---|
20.07.23 · Business Wire (engl.)  |
30.06.23 · Business Wire (engl.) |
Werte aus der Branche Pharmaindustrie
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 10,000 | +36,31 | |
| 120,18 | +20,00 | |
| 0,5110 | +18,56 | |
| 229,50 | +12,83 | |
| 37,55 | +11,92 |
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 0,6460 | -19,25 | |
| 4,0000 | -20,00 | |
| 1,0000 | -33,77 | |
| 0,7500 | -35,34 | |
| 2,1000 | -47,50 |
Beitrag zu dieser Diskussion schreiben
Feedback
Antwort auf Beitrag Nr.: 37.216.491 von future_trader am 20.05.09 10:43:43Medigene macht ja heute auch mal ausnahmsweise Freude... 
Antwort auf Beitrag Nr.: 37.216.491 von future_trader am 20.05.09 10:43:43Natürlich nicht... 
Ich hoff, ich bereu es nicht irgendwann...
Ich hoff, ich bereu es nicht irgendwann...
Antwort auf Beitrag Nr.: 37.216.371 von blb am 20.05.09 10:31:13ich hoffe du bist nicht ausgestiegen? ;-)
Antwort auf Beitrag Nr.: 37.216.141 von future_trader am 20.05.09 10:09:16Der eine Typ aus dem CC hat auch das Kursziel angehoben. Von 5 auf 7 Dollar...
Antwort auf Beitrag Nr.: 37.215.433 von VaJo am 20.05.09 09:09:22versuche mal den webcast mir anzuhören.
Kann aber nichts versprechen.
Kann aber nichts versprechen.
Trading Spotlight
Antwort auf Beitrag Nr.: 37.215.528 von VaJo am 20.05.09 09:17:02sehr gute Aussichten.
Langsam wird sppi entdeckt. weiterhin super spannend.
Langsam wird sppi entdeckt. weiterhin super spannend.
Spectrum Phamaceuticals (SPPI) Small Biotech Explosive Rally Continues!
report
May 19, 2009 – Comments (0) | RELATED TICKERS: SPPI
SPPI broke key resistance above $4.40. On Monday, Mlay 18, 2009, they came out with earnings of $.02 per shares versus estimates of ($.11). As of March 31, 2009 they had approximately $64 million ($1.97 per share) of cash, cash equivalents, and marketable securities. Around July 2, 2009 they have a PDUFA action date by the FDA and another one in October 2009. Based on the current stock price they should be included in one of the Russell indices that reconsitute in July 2009 based on market capitalization as of May 31, 2009. Inclusion in one of the Russell indices will spark additional institutional buying in June 2009. Also, once it breaks $5 per share additional institutional buying should occur.
I expect the stock to be trading between $7-$8 before the July 2, 2009 PDUFA decision from the FDA. This stock could easily be above $10 by the end of July 2009.
On Wednesday, May 6, 2009 the CEO and CFO purchased 290,000 and 85,000 shares, respectively, for $2.70 each. In July 2009, it should receive a decision from the FDA regarding an amendment to its Supplemental Biologics License Application for the use of Zevalin as a treatment for patients with indolent B-cell non Hodgkin's lymphoma (NHL). In Feb 2009, SPPI acquired 100% ownership of Zevalin from Cell Therapeutics, Inc (CTI).
This stock is a good swing trade with short-term upside of between $5-$8. Long-term if its other clincal trials are successful could offer significant upside potential.
report
May 19, 2009 – Comments (0) | RELATED TICKERS: SPPI
SPPI broke key resistance above $4.40. On Monday, Mlay 18, 2009, they came out with earnings of $.02 per shares versus estimates of ($.11). As of March 31, 2009 they had approximately $64 million ($1.97 per share) of cash, cash equivalents, and marketable securities. Around July 2, 2009 they have a PDUFA action date by the FDA and another one in October 2009. Based on the current stock price they should be included in one of the Russell indices that reconsitute in July 2009 based on market capitalization as of May 31, 2009. Inclusion in one of the Russell indices will spark additional institutional buying in June 2009. Also, once it breaks $5 per share additional institutional buying should occur.
I expect the stock to be trading between $7-$8 before the July 2, 2009 PDUFA decision from the FDA. This stock could easily be above $10 by the end of July 2009.
On Wednesday, May 6, 2009 the CEO and CFO purchased 290,000 and 85,000 shares, respectively, for $2.70 each. In July 2009, it should receive a decision from the FDA regarding an amendment to its Supplemental Biologics License Application for the use of Zevalin as a treatment for patients with indolent B-cell non Hodgkin's lymphoma (NHL). In Feb 2009, SPPI acquired 100% ownership of Zevalin from Cell Therapeutics, Inc (CTI).
This stock is a good swing trade with short-term upside of between $5-$8. Long-term if its other clincal trials are successful could offer significant upside potential.
Kann jemand heute abend den Webcast verfolgen? Ich bin nicht zu Hause. Wäre nett wenn jemand kurz den Inhalt wiedergeben könnte.
Wenn man die hochgezockten und hochverschuldeten Pommesbuden wie z.b. CTIC anschaut ist die MK immer noch beschämend.
10 Dollar sollten als PPS schon stehen.
10 Dollar sollten als PPS schon stehen.
Das Gute an dem Anstieg ist ein sehr starkes Volumen.
Gestern über 1 Mio. gehandelte shares. -> sehr gut!!!
After hours Handel bei $5,0 ebenfalls postiv im Vergleich zum Schlusskurs!
Gestern über 1 Mio. gehandelte shares. -> sehr gut!!!
After hours Handel bei $5,0 ebenfalls postiv im Vergleich zum Schlusskurs!
Durchsuchen
